Last reviewed · How we verify

CARBON DIOXIDE, USP (CARBON DIOIDE)

NEXAIR LLC · FDA-approved approved ✓ Verified May 2026 Quality 6/100

CARBON DIOXIDE, USP (generic name: CARBON DIOIDE) is a drug developed by NEXAIR LLC. It is currently FDA-approved.

Carbon dioxide, USP is a small molecule used in medical interventions such as fractional CO2 vaginal laser therapy for recurrent urinary tract infections. It has been studied in clinical trials for various conditions including urinary tract infections, lung cancer, and nonsmall cell lung cancer.

At a glance

Generic nameCARBON DIOIDE
SponsorNEXAIR LLC
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CARBON DIOXIDE, USP

What is CARBON DIOXIDE, USP?

CARBON DIOXIDE, USP (CARBON DIOIDE) is a pharmaceutical drug developed by NEXAIR LLC.

Who makes CARBON DIOXIDE, USP?

CARBON DIOXIDE, USP is developed and marketed by NEXAIR LLC (see full NEXAIR LLC pipeline at /company/nexair-llc).

What is the generic name of CARBON DIOXIDE, USP?

CARBON DIOIDE is the generic (nonproprietary) name of CARBON DIOXIDE, USP.

What development phase is CARBON DIOXIDE, USP in?

CARBON DIOXIDE, USP is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing